Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study

Autor: T. Uhlig, L. F. Karoliussen, J. Sexton, T. K. Kvien, E. A. Haavardsholm, F. Perez-Ruiz, H. B. Hammer

Abstract A gout attack may evolve after a purine-rich diet or alcohol and after starting urate-lowering therapy (ULT). The relationships between fluctuation and change in serum urate (SU) with the occurrence of flares were investigated in this study.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c073d32f356990a60f8518ab9b78906
http://hdl.handle.net/10852/97909

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

SP0167 Renal urate transporters (SUMMARY FOR CLINICIANS)

Autor: F. Perez Ruiz

Publikováno v: SATURDAY, 16 JUNE 2018.

Gout was, and still is in some academic environments, a “metabolic” disease. The advent of allopurinol in the mid of the XXth century, the first xanthine-oxidase inhibitor, precluded that most subjects with “primary gout” were to suffer from

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ec598479a6aa4c90316fc770ebf74912
https://doi.org/10.1136/annrheumdis-2018-eular.7820

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): A large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia

Autor: T. M. MacDonald, I. Ford, G. Nuki, I. S. Mackenzie, R. De Caterina, E. Findlay, J. Hallas, C. J. Hawkey, S. Ralston, M. Walters, J. Webster, J. McMurray, F. Perez Ruiz, C. G. Jennings, T. MacDonald, I. Mackenzie, C. Hawkey, F. Perez-Ruiz, A. Maseri, G. Murray, H. Bird, M. Petrie, M. MacDonald, P. Jhund, W. Saywood, R. Flynn, S. Kean

Publikováno v: Europe PubMed Central
MacDonald, T M, Ford, I, Nuki, G, Mackenzie, I S, De Caterina, R, Findlay, E, Hallas, J, Hawkey, C J, Ralston, S, Walters, M, Webster, J, McMurray, J, Perez Ruiz, F & Jennings, C G 2014, ' Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST) : a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia ', BMJ Open, vol. 4, no. 7, pp. e005354 . https://doi.org/10.1136/bmjopen-2014-005354
MacDonald, T M, Ford, I, Nuki, G, Mackenzie, I S, De Caterina, R, Findlay, E, Hallas, J, Hawkey, C J, Ralston, S, Walters, M, Webster, J, McMurray, J, Ruiz, F P & Jennings, C G 2014, ' Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia ', B M J Open, vol. 4, no. 7, e005354 . https://doi.org/10.1136/bmjopen-2014-005354
BMJ Open

Introduction: Gout affects 2.5% of the UK's adult population and is now the most common type of inflammatory arthritis. The long-term management of gout requires reduction of serum urate levels and this is most often achieved with use of xanthine oxi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8da2d78b142b7212c01e8f5196c18fe
https://acuresearchbank.acu.edu.au/item/8708y/protocol-of-the-febuxostat-versus-allopurinol-streamlined-trial-fast-a-large-prospective-randomised-open-blinded-endpoint-study-comparing-the-cardiovascular-safety-of-allopurinol-and-febuxostat-in

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.